ArticleClinical rheumatology2026
A pilot study on the efficacy and mechanism of telitacicept in systemic lupus erythematosus with antiphospholipid syndrome.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionAntiphospholipid syndrome (APS) is a common complication of systemic lupus erythematosus (SLE). Current treatment mainly relies on anticoagulation. Whether telitacicept can reduce antiphospholipid antibodies (aPLs) and its mechanism remain understudied. This study aims to investigate the effect of telitacicept on reducing aPLs and its impact on B lymphocyte subsets in patients with APS secondary to SLE.
methodThis exploratory, multicenter, prospective, single-arm, pre-post design study enrolled patients with APS secondary to SLE. Subcutaneous telitacicept 160 mg once weekly was added to stable standard therapy, with a 6-month follow-up. Standard treatment included glucocorticoids, hydroxychloroquine, immunosuppressants for SLE, and antiplatelet or anticoagulant therapy for APS. Medication types and doses had remained stable for at least 2 months within the 6 months prior to enrollment. Primary outcome measures included changes in aPLs, B lymphocyte subsets, and incidence of new thrombotic events and adverse reactions.
resultsThis study enrolled 11 female patients. At 6 months of treatment, anticardiolipin antibodies (aCLs)-IgG/IgM and anti-β2-glycoprotein I antibodies (anti-β2GPI)-IgG/IgM were significantly reduced (P < 0.05). Lupus anticoagulant (LA) showed a decreasing trend but without statistical significance. Total B cells, transitional B cells, and naive B cells decreased significantly. Erythrocyte sedimentation rate (ESR) improved significantly at 6 months. No new thrombotic events or adverse reactions occurred during follow-up.
conclusionsTelitacicept is associated with a reduction in aPLs levels in patients with APS secondary to SLE, potentially by inhibiting total B cells, transitional B cells, and naive B cells, with a favorable safety profile. Key Points • Telitacicept is widely used for SLE in mainland China. Our study shows it is also effective in SLE patients with APS, filling an evidence gap. • Standard APS therapy does not lower autoantibody levels. Telitacicept reduces aPLs (including aCL and anti-β2GPI), offering a novel immunological strategy. • Our findings suggest telitacicept lowers aPLs by inhibiting B cell differentiation and maturation, providing mechanistic insights into its efficacy in APS secondary to SLE.
Indexed as
Identifiers
42295544What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.